Biomagnetics Diagnostics Corp. Appoints Charles Gregoire de Rothschild Special Adviser to Board

Rothschild Family Pushes for More Effective Malaria Testing and Diagnostic Tools

NEW YORK--(Business Wire)--
Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a producer of revolutionary
diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis
testing today announced the appointment of international financier Charles
Gregoire de Rothschild to the role of special adviser to the Company's board of
directors. Mr. de Rothschild will support Biomagnetics` continuing global
expansion efforts by leveraging his extensive domestic and international
financial expertise.

"Western countries are finally waking up to the ongoing malaria crisis, which
claims more than one million lives each year. While there have been some notable
gains in malaria prevention over the past few years, the area of malaria testing
and diagnostics has progressed very slowly. The world is in desperate need of
low-cost, field deployable tools to diagnose malaria," said Mr. de Rothschild.

For nearly 100 years, the direct microscopic visualization of the malaria
parasite on blood smears has been the accepted method of diagnostics of malaria
in most settings. This process must usually be performed in a laboratory setting
by trained personnel. While field deployable, non-microscopic tests have been
introduced, the efficacy of these tests is often called into question.

Mr. de Rothschild continued, "The Rothschild family wishes to do its part to
advance this area of research and will be providing its support to develop
better diagnostic tools. We have reviewed the technology under development by
Biomagnetics Diagnostics and believed it to be revolutionary, holding the
potential to cut the cost of testing by nearly two thirds. Additionally, because
the technology is handheld, portable and easy to use, testing can be conducted
by relatively untrained medical personnel. We believe the development of this
technology could potentially save tens of thousands of lives each year and we
wish to help speed its entry to market."

According to the World Health Organization, some 3.2 billion people, or about
half the world's population is at risk of malaria transmission in 107 countries
and territories worldwide. While there are between 350 million and 500 million
new cases of malaria each year, there are very few reliable and field deployable
diagnostic tools available. Early detection substantially improves treatability
and survivability. Field deployable integrated optical biosensor systems, such
as those under development at Biomagnetics Diagnostics, hold the promise to
significantly speed the diagnostic testing process and to meaningfully lower
costs.

About Biomagnetics Diagnostics Corp.

Biomagnetics Diagnostics Corporation is an advanced medical device and
biotechnology company. The Company`s revolutionary diagnostic systems, which are
based on advanced magnetics, test for any viral or bacterial disease using any
body fluid. The Company's technology allows laboratories to perform far more
tests in the same amount of time it takes to do a single test. The HTS-MTP
platform is designed to detect the actual virus and viral load in body fluids
and not just simply screen for the presence of viral antibodies. More
information on Biomagnetics Diagnostics Corp. can be seen at
www.BiomagneticsBMGP.com

Biomagnetics Diagnostics Corp.
Joe Noel, 925-922-2560

Copyright Business Wire 2009